Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Antengene Corporation Limited ( (HK:6996) ) is now available.
Antengene Corporation Limited announced that the China National Medical Products Administration has approved the investigational new drug application for a Phase Ib/II study of ATG-022 in combination with KEYTRUDA and chemotherapy. This approval marks a significant step for Antengene in advancing its clinical pipeline and strengthening its position in the biotech industry, potentially offering new treatment options for diseases with unmet medical needs.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. The company’s pipeline ranges from preclinical to commercial stages, featuring several in-house discovered programs and a proprietary T cell engager platform. Antengene has obtained numerous investigational new drug approvals across the U.S. and Asia, and its lead commercial asset, XPOVIO, is approved in multiple Asia Pacific markets.
Average Trading Volume: 4,431,960
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.87B
For detailed information about 6996 stock, go to TipRanks’ Stock Analysis page.